Abstract
Background Antibiotic resistance is a persistent and growing concern. Our objective was to analyze antibiotic prescribing data in the United States (US) to identify trends in the Medical Expenditure Panel System (MEPS) and any state-level disparities to Medicaid patients.
Methods We obtained total MEPS prescriptions for eight antibiotics from 2013 to 2020. We extracted prescribing rates per 1,000 Medicaid enrollees for two years, 2018 and 2019, for four broad spectrum (azithromycin, ciprofloxacin, levofloxacin, and moxifloxacin) and four narrow spectrum (amoxicillin, cephalexin, doxycycline, and trimethoprim/sulfamethoxazole) antibiotics.
Results Antibiotics in MEPS decreased from 2013 to 2020 by −38.7% with a larger decline for broad (−53.7%) than narrow spectrum (−23.5%). Antibiotic prescriptions decreased from 2018 to 2019 and by −6.7% when correcting for the number of Medicaid enrollees. Amoxicillin was the predominant antibiotic followed by azithromycin, cephalexin, trimethoprim/sulfamethoxazole, doxycycline, ciprofloxacin, levofloxacin, and moxifloxacin. Substantial geographic variation in antibiotic prescribing existed with 2.8-fold between the highest (Kentucky = 855/1,000) and lowest (Oregon = 299) states. The South prescribed 52.2% more antibiotics (580/1,000) than the West (381/1,000). There were significant correlations across states in antibiotic prescribing.
Conclusions & Relevance This study identified sizable disparities by geography in prescribing rates of eight antibiotics with over three-fold state level differences. The South had the highest prescribing rates among all the regions. Areas with high antibiotic prescribing rates, particularly for outpatients, may benefit from programs to reduce potentially unnecessary prescribing. Further analysis of state level Medicaid or prescribing policies is needed to identify reasons for the variation in prescribing rates.
Competing Interest Statement
BJP was (2019-2021) part of an osteoarthritis research team supported by Pfizer and Eli Lilly. The other authors have no disclosures.
Funding Statement
This research was supported by the Health Resources Services Administration (D34HP31025).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This research was supported by the Health Resources Services Administration (D34HP31025).
Conflicts of interest: BJP was (2019-2021) part of an osteoarthritis research team supported by Pfizer and Eli Lilly. The other authors have no disclosures.
Data Availability
All data produced are available online at https://data.medicaid.gov/
